<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02252406</url>
  </required_header>
  <id_info>
    <org_study_id>WIRB20141202</org_study_id>
    <nct_id>NCT02252406</nct_id>
  </id_info>
  <brief_title>Impact of Ranolazine in Blood Markers in Women With Angina and Metabolic Syndrome</brief_title>
  <acronym>IRMA</acronym>
  <official_title>Impact of Ranolazine on Inflammatory, Thrombogenic, Lipogenic, Biomarkers in Women With Angina and Metabolic Syndrome.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of ranolazine on different markers of&#xD;
      cardiometabolic disease in women with stable angina.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluate the ability of ranolazine to favorably modify thrombogenic, inflammatory, lipogenic,&#xD;
      oxidative stress and hormonal biomarkers in a relatively short period of time in a group of&#xD;
      ethnically diverse women with chronic stable angina and metabolic syndrome.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">May 17, 2019</completion_date>
  <primary_completion_date type="Actual">December 17, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Impact of Ranolazine on Hemoglobin A1C</measure>
    <time_frame>Change from baseline to 24 weeks</time_frame>
    <description>Will evaluate the impact of ranolazine in HgbA1C in women with Metabolic Syndrome (MBS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Impact of Ranolazine on HDL-C Levels in Subjects</measure>
    <time_frame>Change from Baseline to 24 weeks</time_frame>
    <description>Will evaluate the impact of ranolazine in HDL-C levels in women with metabolic syndrome</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Stable Angina</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Ranolazine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ranolazine would start with 500 mg BID and be force titrated to 1 gram po BID after 3 weeks. Down titration would only be allowed for side effects. This would be on top of all standard medical therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo arm would start with 500 mg matching placebo tablet BID and be force titrated to 1 gram matching placebo tablet twice a day after 3 weeks. Down titration would only be allowed for side effects (if reported). This would be on top of all standard medical therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranolazine</intervention_name>
    <description>Ranolazine 500 mg from baseline to week 3 and 1000 mg thereafter until week 24</description>
    <arm_group_label>Ranolazine</arm_group_label>
    <other_name>Ranexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo tablets daily for 24 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with chronic stable angina (&gt; 3 months) on evidence based adequate therapy&#xD;
&#xD;
          -  Evidence of stable coronary artery disease by any of these:&#xD;
&#xD;
          -  MI, PCI or CABG &gt; 30 days prior to enrollment or&#xD;
&#xD;
          -  Angiography showing &gt; 50% stenosis in major vessel, branch or bypass graft &gt; 30 days&#xD;
             of enrollment or&#xD;
&#xD;
          -  Abnormal stress MPI nuclear study, or DBA stress echo where the decision has been to&#xD;
             treat medically and where angina has remained stable for &gt;= 3 months&#xD;
&#xD;
          -  Evidence of the Metabolic Syndrome: As defined by ATP III criteria i.e 3/5 of&#xD;
             following Abdominal circumference F &gt; 88 cm (35 in), M &gt; 102 cm (40 in)&#xD;
             Hypertriglyceridemia ≥ 150 mg/dl HDL F &lt; 50 mg/dl M &lt; 40 mg/dl Blood Pressure ≥130/85&#xD;
             Fasting Glucose ≥100 mg/dl For reproductive age women, a negative urine pregnancy test&#xD;
             is required if all other inclusion criteria are met.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Exclusion of patients with contraindications to use of RANEXA, including patients on&#xD;
             CYP3A4 inducers/potent inhibitors, and patients with liver cirrhosis.&#xD;
&#xD;
          -  Exclusion of Patients with CrCl &lt; 30 mL/min&#xD;
&#xD;
          -  Limit dose of RANEXA to 500mg BID in patients on concurrent diltiazem/ verapamil&#xD;
&#xD;
          -  Limit concurrent simvastatin to 20 mg/day&#xD;
&#xD;
          -  Limit concurrent metformin to 1700 mg/day Additional Exclusion&#xD;
&#xD;
          -  Patients with variable -inconsistent symptoms&#xD;
&#xD;
          -  Patients with unstable coronary artery disease or revascularization within 30 days of&#xD;
             enrollment.&#xD;
&#xD;
          -  Patients who have known severe liver disease.&#xD;
&#xD;
          -  Patients already receiving maximal ranolazine therapy for more than 4 weeks&#xD;
&#xD;
          -  Presence of diabetes (AIC≥ 6.5 and /or on insulin therapy or anti-diabetic medication&#xD;
             other than metformin) unstable hypothyroidism, active infection, active cancer (or&#xD;
             ongoing chemotherapy and/or radiation within a year who are not on remission) and/or&#xD;
             recent major surgery or illness.&#xD;
&#xD;
          -  Patients with any contraindication to ranolazine see above&#xD;
&#xD;
          -  Women of reproductive age are excluded if they are planning to become pregnant in the&#xD;
             next 6 -12 months after randomization.&#xD;
&#xD;
          -  Patients who are pregnant or lactating&#xD;
&#xD;
          -  Documented allergic reaction to ranolazine in the past.&#xD;
&#xD;
          -  Unexplained prolongation of the QTc &gt; 500 milliseconds.&#xD;
&#xD;
          -  Current or planned co-administration of moderate CYP3A inhibitors (eg, diltiazem,&#xD;
             verapamil, aprepitant, erythromycin, fluconazole, and grapefruit juice or&#xD;
             grapefruit-containing products) is not a full contraindication, if meet inclusion&#xD;
             criteria otherwise, these patients could be accepted in trial but dose will be limited&#xD;
             to 500 mg BID as stated previously.&#xD;
&#xD;
          -  Current or planned co-administration of strong CYP3A inhibitors (eg, ketoconazole,&#xD;
             itraconazole, clarithromycin, nefazodone, nelfinavir, ritonavir, indinavir, and&#xD;
             saquinavir) OR strong CYP3A inducers (eg, rifampin, rifabutin, rifapentine,&#xD;
             phenobarbital, phenytoin,carbamazepine, and St. John's Wort) is a contraindication.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gladys P Velarde, MD, FACC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 11, 2014</study_first_submitted>
  <study_first_submitted_qc>September 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2014</study_first_posted>
  <results_first_submitted>February 7, 2020</results_first_submitted>
  <results_first_submitted_qc>March 27, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 10, 2020</results_first_posted>
  <last_update_submitted>March 27, 2020</last_update_submitted>
  <last_update_submitted_qc>March 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stable Angina</keyword>
  <keyword>Metabolic Syndrome</keyword>
  <keyword>Women</keyword>
  <keyword>Biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranolazine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 25, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/06/NCT02252406/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period: 7/21/14 - 7/2/18 Location: UF Jacksonville Outpatient Cardiology clinic</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Ranolazine</title>
          <description>Ranolazine would start with 500 mg BID and be force titrated to 1 gram po BID after 3 weeks. Down titration would only be allowed for side effects. This would be on top of all standard medical therapy.&#xD;
Ranolazine: Ranolazine 500 mg from baseline to week 3&#xD;
Ranolazine: Ranolazine 1000mg daily at week 3 until weeks 24.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo arm would start with 500 mg matching placebo tablet BID and be force titrated to 1 gram matching placebo tablet twice a day after 3 weeks. Down titration would only be allowed for side effects (if reported). This would be on top of all standard medical therapy.&#xD;
Placebo: Matching placebo tablets daily for 24 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Starting Dose Ranolazine 500 mg BID</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Titrated to Ranolazine 1000mg BID</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ranolazine</title>
          <description>Ranolazine would start with 500 mg BID and be force titrated to 1 gram po BID after 3 weeks. Down titration would only be allowed for side effects. This would be on top of all standard medical therapy.&#xD;
Ranolazine: Ranolazine 500 mg from baseline to week 3&#xD;
Ranolazine: Ranolazine 1000mg daily at week 3 until weeks 24.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo arm would start with 500 mg matching placebo tablet BID and be force titrated to 1 gram matching placebo tablet twice a day after 3 weeks. Down titration would only be allowed for side effects (if reported). This would be on top of all standard medical therapy.&#xD;
Placebo: Matching placebo tablets daily for 24 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Impact of Ranolazine on Hemoglobin A1C</title>
        <description>Will evaluate the impact of ranolazine in HgbA1C in women with Metabolic Syndrome (MBS)</description>
        <time_frame>Change from baseline to 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ranolazine Treated</title>
            <description>We looked women randomized by table randomization to ranolazine that successfully titrated to maximum dose of tested drug (1,000 mg bid)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>We looked women randomized by table randomization to placebo that successfully titrated to maximum dose of placebo drug</description>
          </group>
        </group_list>
        <measure>
          <title>Impact of Ranolazine on Hemoglobin A1C</title>
          <description>Will evaluate the impact of ranolazine in HgbA1C in women with Metabolic Syndrome (MBS)</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5" spread="6.2"/>
                    <measurement group_id="O2" value="2.6" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Impact of Ranolazine on HDL-C Levels in Subjects</title>
        <description>Will evaluate the impact of ranolazine in HDL-C levels in women with metabolic syndrome</description>
        <time_frame>Change from Baseline to 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ranolazine Treated</title>
            <description>We looked women randomized by table randomization to ranolazine that successfully titrated to maximum dose of tested drug (1,000 mg bid)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>We looked women randomized by table randomization to placebo that successfully titrated to maximum dose of placebo drug</description>
          </group>
        </group_list>
        <measure>
          <title>Impact of Ranolazine on HDL-C Levels in Subjects</title>
          <description>Will evaluate the impact of ranolazine in HDL-C levels in women with metabolic syndrome</description>
          <units>percentage of change in HDL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="15.7"/>
                    <measurement group_id="O2" value="6.5" spread="46.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Patients were followed for 24 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ranolazine Treated</title>
          <description>Ranolazine would start with 500 mg BID and be force titrated to 1 gram po BID after 3 weeks. Down titration would only be allowed for side effects. This would be on top of all standard medical therapy</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo arm would start with 500 mg matching placebo tablet BID and be force titrated to 1 gram matching placebo tablet twice a day after 3 weeks. Down titration would only be allowed for side effects (if reported). This would be on top of all standard medical therapy.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>upset stomach</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gladys Velarde, MD</name_or_title>
      <organization>University of Florida, Jacksonville</organization>
      <phone>904-244-2060</phone>
      <email>gladys.velarde@jax.ufl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

